Amy Hayes, NP
Family · Rochester, NYNPI 1427220169
Payments from drug & device makers
Across 752 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Phathom Pharmaceuticals, Inc.$618
- Pentax Of America, Inc.$561
- plus $5K from 26 others
What the payments were for
- Food & beverage$12,41794%
- Education$3182%
- Other$5424%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 163 | $2,596 |
| Johnson & Johnson(2 entities) | 63 | $1,403 |
| Takeda Pharmaceuticals U.S.A., Inc. | 84 | $1,402 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 124 | $1,226 |
| Phathom Pharmaceuticals, Inc. | 39 | $618 |
| Pentax Of America, Inc. | 3 | $561 |
| Ardelyx, Inc. | 25 | $543 |
| Regeneron Healthcare Solutions, Inc. | 20 | $486 |
| Lilly USA, LLC | 28 | $482 |
| QOL Medical, LLC | 26 | $442 |
| Ironwood Pharmaceuticals, Inc | 23 | $409 |
| Madrigal Pharmaceuticals | 7 | $403 |
| Bristol Myers Squibb | 32 | $400 |
| Pfizer | 17 | $356 |
| Intercept Pharmaceuticals, Inc. | 20 | $287 |
| Gilead | 12 | $256 |
| Sanofi | 11 | $243 |
| Merck | 12 | $242 |
| Boehringer Ingelheim | 7 | $166 |
| Amgen | 5 | $113 |
| Ipsen Biopharmaceuticals, Inc | 5 | $112 |
| Celltrion USA Inc. | 5 | $105 |
| Redhill Biopharma Inc. | 3 | $68 |
| Sandoz | 3 | $67 |
| Novo Nordisk | 2 | $62 |
| Nestle Healthcare Nutrition Inc. | 3 | $49 |
| Ferring Pharmaceuticals Inc. | 3 | $48 |
| Alnylam Pharmaceuticals Inc. | 2 | $40 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Organon | 1 | $21 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIDEO COLONOSCOPE$542
- REZDIFFRA$252
- Tremfya$130
- OMVOH$111
How this compares
$13,278 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 24 | $657,071 |
| LinzessLinaclotide | 172 | $142,846 |
| XifaxanRifaximin | 23 | $87,891 |
| CreonLipase/Protease/Amylase | 47 | $69,742 |
| Mesalamine | 99 | $43,599 |
| ZenpepLipase/Protease/Amylase | 15 | $31,072 |
| Dexlansoprazole DrDexlansoprazole | 118 | $27,334 |
| Mesalamine ErMesalamine | 98 | $22,127 |
| Esomeprazole Magnesium | 500 | $16,859 |
| MotegrityPrucalopride Succinate | 25 | $13,436 |
| Ursodiol | 53 | $12,950 |
| Famotidine | 1,068 | $12,523 |
| Budesonide DrBudesonide | 73 | $11,493 |
| VoqueznaVonoprazan Fumarate | 12 | $10,443 |
| Mesalamine DrMesalamine | 11 | $8,980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,403 | $657,07124 claims |
| AbbVieLinzess, Creon | $2,596 | $212,588219 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Apriso | $1,226 | $95,43635 claims |
| Aimmune Therapeutics, Inc.Zenpep | $22 | $31,07215 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,402 | $13,43625 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $618 | $10,44312 claims |
| Redhill Biopharma Inc.Movantik | $68 | $7,04611 claims |
| SandozLansoprazole | $67 | $2,792119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Rochester
- Stephanie BartlettRochester$63K
- Orlando HarrisRochester$30K
- Laron NelsonRochester$28K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.